References
- Ries, L., Wingo, P.A., Miller, S.S., Howe, H., Weir, H.K., Rosenberg, H.M., Vernon, S.W., Cronin, K., Edwards, B.K. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 88, 2398-2424, 2000 https://doi.org/10.1002/(SICI)1097-0142(20000515)88:10<2398::AID-CNCR26>3.0.CO;2-I
- Fisher, B., Costantino, J.P., Wickerham, D.L., Redmond, C.K., Kavanah, M., Cronin, W.M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., Wolmaik, N. other National Surgical Adjuvant Breast and Bowel Project Investigators. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 18, 1371-1388, 1998
- Kroncke, K.D., Fehsel, K., Suschek, C., Kolb-Bachofen, V. Inducible nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell survival. Int. Immunopharmacol. 1, 1407-1420, 2001 https://doi.org/10.1016/S1567-5769(01)00087-X
- Tamir, S., Tannenbaum, S.R. The role of nitric oxide (NO) in the carcinogenic process. Biochim. Biophys. Acta. 1288, F31-F36, 1996
- Ambs, S., Hussain, S.P., Harris, C.C. Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J. 11, 443-448, 1997 https://doi.org/10.1096/fasebj.11.6.9194524
- Knowles, R.G., Moncada, S. Nitric oxide synthases in mammals. Biochem. J. 298, 249-258, 1994 https://doi.org/10.1042/bj2980249
- Thomsen, L.L., Miles, D.W., Happerfield, L., Bobrow, L.G., Knowles, R.G., Moncada, S. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer 72, 41-44, 1995 https://doi.org/10.1038/bjc.1995.274
- Li, L., Carol, T., Susan, K.G. Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverse spontaneous tumors in ODC/Ras transgenic mice. Cancer Res. 60, 5696-5730, 2000
- Huber, M., Poulin, R. Permissive role of polyamines in the cooperative action of estrogens and insulin or insulin-like growth factor I on human breast cancer cell growth. J. Clin. Endocrinol. Metab. 81, 113-123, 1996 https://doi.org/10.1210/jc.81.1.113
- 康秉秀. 本草學, 永林社, 서울, p 169, 1991
- 김동일. 鄕藥集成方, 여강출판사, 서울, p 152, 1991
- Macchiarini, P., Fontanini, G., Hardin, M.J., Squartini, F., Angeletti, C.A. Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet 340, 145-146, 1992 https://doi.org/10.1016/0140-6736(92)93217-B
- Wink, D.A., Hanbauer, I., Grisham, M.B., Laval, F., Nims, R.W., Laval, J., Cook, J., Pacelli, R., Liebmann, J., Krishna, M., Ford, P.C., Mitchell, J.B. Chemical biology of nitric oxide: regulation and protective and toxic mechanisms. Curr. Top. Cell Regul. 34, 159-187, 1996 https://doi.org/10.1016/S0070-2137(96)80006-9
- Ambs, S., Bennett, W.P., Merriam, W.G., Ogunfusika, M.O., Oser, S.M., Harrington, A.M., Shields, P.G., Felley-Bosco, E., Hussain, S.P., Harris, C.C. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J. Natl. Cancer Inst. 91, 86-88, 1999 https://doi.org/10.1093/jnci/91.1.86
- Vakkala, M., Kahlos, K., Lakari, E., Paakko, P., Kinnula, V., Soini, Y. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in situ and invasive breast carcinomas. Clin. Cancer Res. 6, 2408-2416, 2000
- Robbins, R.A., Barnes, P.J., Springall, D.R., Warren, J.B., Kwon, O.J., Buttery, L.D., Wilson, A.J., Geller, D.A., Polak, J.M. Expression of inducible nitric oxide in human lung epithelial cells. Biochem. Biophys. Res. Comm. 203, 209-218, 1994 https://doi.org/10.1006/bbrc.1994.2169
- Tschugguel, W., Knogler, W., Czerwenka, K., Mildner, M., Weninger, W., Zeillinger, R., Huber, J.C. Presence of endothelial calcium-dependent nitric oxide synthase in breast apocrine metaplasia. Br. J. Cancer 74, 1423-1426, 1996 https://doi.org/10.1038/bjc.1996.559
- Manni, A., Astrow, S.H., Gammon, S., Thompson, J., Mauger, D., Washington, S. Immunohistochemical detection of ornithine-decarboxylase in primary and metastatic human breast cancer specimens. Breast Cancer Res. Treat. 67, 147-156, 2001 https://doi.org/10.1023/A:1010697218986
- Glikman, P., Vegh, J., Pollina, M.A., Mosto, A.H., Levy, C.M. Ornithine decarboxylase activity, prolactin blood levels, and estradiol and progesterone receptors in human breast cancer. Cancer (Phila) 60, 2237-2243, 1987 https://doi.org/10.1002/1097-0142(19871101)60:9<2237::AID-CNCR2820600923>3.0.CO;2-J
- Suh, N., Glasebrook, A.L., Palkowitz, A.D., Bryant, H.U., Burris, L.L., Starling, J.J., Pearce, H.L., Williams, C., Peer, C., Wang Y., Sporn, M.B. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res. 61, 8412-8415, 2001
- Marton, L.J., Pegg, A.E. Polyamines as targets for therapeutic intervention. Annu. Rev. Pharmacol. Toxicol. 35, 55-91, 1995 https://doi.org/10.1146/annurev.pa.35.040195.000415
- Green, J.E., Shibata, M.A., Shibata, E., Moon, R.C., Anver, M.R., Kelloff, G., Lubet, R. 2-Difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res. 61, 7449-7455, 2001